cell-therapy

Documents about cell-therapy

• CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma#849149ClinicalTrials.gov
• Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued With a Tyrosine Kinase Inhibitor in Patients With Metastatic Renal Cell Carcinoma (RCC) and Disease Control#148760ClinicalTrials.gov
• Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical Trial#432896ClinicalTrials.gov
• T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive#800372ClinicalTrials.gov
• Causal modeling reveals cell–cell communication dynamics in the tumor microenvironment during anti-PD-1 therapy in breast cancer patients.#67452NCBI PubMed Central
• Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer#230413ClinicalTrials.gov
• FAP-CD40 and PD1-IL2v combination therapy reprograms immunologically cold tumors through de novo intratumoral T cell-dendritic cell clusters.#251064NCBI PubMed Central
• Vaccine Therapy in Treating Patients With Non-Small Cell Lung Cancer (NSCLC) Stages IIIB/IV#283104ClinicalTrials.gov
• Advances in cancer immunotherapy: adoptive cell therapy and immune cell engagers in solid tumours#299165Springer Nature OA
• Study of 90Y-DOTA-hLL2 as a Consolidation Therapy After R-CHOP in Patients With Diffuse Large B-cell Lymphoma#349965ClinicalTrials.gov
• A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS)#414386ClinicalTrials.gov
• Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer#801914ClinicalTrials.gov
• WAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLC#805056ClinicalTrials.gov
• Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym#834684ClinicalTrials.gov
• Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma#842052ClinicalTrials.gov
• The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer#858530ClinicalTrials.gov
• Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma#307460ClinicalTrials.gov
• Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma#467578ClinicalTrials.gov
• Study of Low Dose Chemotherapy Plus Sorafenib as Initial Therapy for Patients With Advanced Non-Squamous Cell NSCLC#830554ClinicalTrials.gov
• Quantifying Systemic Immunosuppression to Personalize Cancer Therapy#861951ClinicalTrials.gov
• Vaccine Therapy in Treating Patients With Non-Small Cell Lung Cancer#141103ClinicalTrials.gov
• Endothelial Cell Therapy for the Acute and Chronic Liver Disease.#150165NCBI PubMed Central
• GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma#231815IRIS
• Cell membrane-derived vesicles for boron neutron capture therapy of glioblastoma#315151IRIS
• Cell-type-directed network-correcting combination therapy for Alzheimer's disease.#388810NCBI PubMed Central
• Vaccine Therapy in Treating Patients With Recurrent Glioblastoma#651132ClinicalTrials.gov
• Phase II Trial of Continuation Therapy in Advanced NSCLC#683088ClinicalTrials.gov
• Autologous Stem Cell Transplantation and Maintenance Therapy for Multiple Myeloma#863257ClinicalTrials.gov
• The Effects of Music Therapy-Based Stress Reduction on Bone Marrow Transplant Recipients#810800ClinicalTrials.gov
• Lisaftoclax Plus Pirtobrutinib in Relapsed or Refractory Mantle Cell Lymphoma After BTK-Targeted Therapy#850167ClinicalTrials.gov
• Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage III or Stage IV Head and Neck Cancer#859399ClinicalTrials.gov
• A Single-Arm Phase II Clinical Study of Docetaxel Combined With Nimotuzumab and Pucotenlimab as Second-Line and Beyond Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma#849539ClinicalTrials.gov
• Chemotherapy, Tirapazamine, and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer#863237ClinicalTrials.gov
• Mechanisms of tumor cell evasion from NK cell-mediated killing and advances in NK cell-based cancer immunotherapy#4574Europe PMC
• Regulatory T cell therapies: biological foundations, engineering strategies, and clinical translation#257538HAL (France)
• A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma#828554ClinicalTrials.gov
• Autologous Stem Cell Transplantation of Cells Engineered to Express Alpha-Galactosidase A in Patients With Fabry Disease#845916ClinicalTrials.gov
• Carrelizumab, Chemotherapy and Apatinib in the Neoadjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma#261502ClinicalTrials.gov
• Sickle cells to super cells: the alluring genetic cure for sickle cell disease#277674RUcore, Rutgers University Community Repository
• N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy#332740ClinicalTrials.gov
• Monoclonal Antibody Therapy in Treating Patients With Progressive Small Cell Lung Cancer (SCLC)#846955ClinicalTrials.gov
• NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung Cancer#862722ClinicalTrials.gov
• The Safety and Clinical Efficacy of RAK Cell Therapy in Late-stage Gastric Cancer: A Randomized Controlled Trial#481752ClinicalTrials.gov
• CAR-T Technology for Recurrent/Refractory Malignant Hematological and Lymphatic Tumors#839162ClinicalTrials.gov
• Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia#234425ClinicalTrials.gov
• Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies#256861ClinicalTrials.gov
• Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy#279528ClinicalTrials.gov
• CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)#837738ClinicalTrials.gov
• Physical Therapy in Patients Undergoing Allo-HSCT With cGVHD#835884ClinicalTrials.gov
• A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer#865729ClinicalTrials.gov